Literature DB >> 31368773

The Effect of Vitamin D Supplementation on Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Jing Gan1,2, Peter Galer3, Dan Ma1, Chao Chen1,2, Tao Xiong1,2,4.   

Abstract

Objective: A systematic review and meta-analysis of randomized controlled trials (RCTs) were conducted to assess the benefits and harms of vitamin D supplementation for attention-deficit/hyperactivity disorder (ADHD) patients.
Methods: We followed the standard methodological procedures of the Cochrane Handbook for Systematic Reviews of Intervention. PubMed, Embase, the Cochrane Central Register of Controlled Trials, Science and Conference Proceedings Citation Index-Social Science and Humanities (Web of Science), ClincalTrials.gov, and World Health Organization's International Clinical Trials Registry Platform were searched for RCTs in January 2019. Independently, two authors (J.G., T.X.) extracted data, assessed the risk of bias, combined the data, and graded evidence quality using the Grading of Recommendations Assessment, Development, and Evaluation approach. Our primary outcomes were assessed through rating scales of ADHD severity. Secondary outcomes measured were the possible adverse effects of vitamin D supplementation and vitamin D status after supplementation for ADHD.
Results: We included four RCTs with 256 children addressing vitamin D supplementation as adjunctive therapy to methylphenidate on ADHD symptoms. Vitamin D supplementation demonstrated a small but statistically significant improvement in ADHD total scores, inattention scores, hyperactivity scores, and behavior scores. The improvement was likely limited due to the low to very low quality of evidence in the literature. There was no statistically significant improvement in oppositional scores. Reported adverse events in the vitamin D group were mild and not significantly different from the control group. Vitamin D supplementation increased serum vitamin D levels and the ratio of patients with sufficient vitamin D levels. Conclusions: Vitamin D supplementation as adjunctive therapy to methylphenidate appeared to reduce ADHD symptoms without serious adverse events, associated with improved vitamin D status. However, considering the generally low strength of evidence, well-designed RCTs are needed to determine the efficacy and safety of vitamin D supplementation for both children and adults with ADHD, especially in the setting of a combination of vitamin D and other ADHD treatments.

Entities:  

Keywords:  attention-deficit/hyperactivity disorder; effect; meta-analysis; supplementation; vitamin D

Year:  2019        PMID: 31368773     DOI: 10.1089/cap.2019.0059

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  4 in total

1.  Role of calcium metabolism in ADHD: The relationship between parathyroid hormone and ADHD symptom severity.

Authors:  Dilek Altun Varmiş; Gamze Yapça Kaypakli; Ayşegül Yolga Tahiroğlu; Ayse Avci; Gonca Gül Çelik; Özge Metin; Selcuk Matyar; Özlem Görüroğlu Öztürk
Journal:  Indian J Psychiatry       Date:  2022-06-08       Impact factor: 2.983

2.  Analysis of Development Trends of the Research Hotspots of Vitamin D in Children.

Authors:  Xuemei Luo; Feifeng Wu; Cheng Wang; Chuan Wen
Journal:  Front Pediatr       Date:  2022-05-06       Impact factor: 3.569

3.  Serum Levels of Vitamin A and Vitamin D and Their Association With Symptoms in Children With Attention Deficit Hyperactivity Disorder.

Authors:  Hong-Hua Li; Xiao-Jing Yue; Cheng-Xin Wang; Jun-Yan Feng; Bing Wang; Fei-Yong Jia
Journal:  Front Psychiatry       Date:  2020-11-23       Impact factor: 4.157

4.  A mendelian randomization study on causal effects of 25(OH)vitamin D levels on attention deficit/hyperactivity disorder.

Authors:  Lars Libuda; Roaa Naaresh; Christine Ludwig; Björn-Hergen Laabs; Jochen Antel; Manuel Föcker; Johannes Hebebrand; Anke Hinney; Triinu Peters
Journal:  Eur J Nutr       Date:  2020-11-27       Impact factor: 5.614

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.